Europese Unie - Maltees - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - immunosoppressanti - jekk jogħġbok irreferi għad-dokument ta 'informazzjoni dwar il-prodott.

Europese Unie - Maltees - EMA (European Medicines Agency)

sanofi-aventis groupe  - irbesartan, hydrochlorothiazide - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali. din il-kombinazzjoni ta 'doża fissa hija indikata f'pazjenti adulti li l-pressjoni tad-demm tagħhom mhix ikkontrollata b'mod adegwat fuq irbesartan jew hydrochlorothiazide waħdu.

Europese Unie - Maltees - EMA (European Medicines Agency)

sanofi winthrop industrie - irbesartan, hydrochlorothiazide - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali. din il-kombinazzjoni ta 'doża fissa hija indikata f'pazjenti adulti li l-pressjoni tad-demm tagħhom mhix ikkontrollata b'mod adegwat fuq irbesartan jew hydrochlorothiazide waħdu.

Europese Unie - Maltees - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - drogi użati fid-dijabete - dijabete mellitus fejn huwa meħtieġ it-trattament bl-insulina. insuman rapid huwa wkoll adattat għall-kura ta 'koma ipergliċemika u ketoaċidożi, kif ukoll għall-kisba ta' stabilizzazzjoni minn qabel, intra u wara l-operazzjoni f'pazjenti bid-dijabete mellitus.

Europese Unie - Maltees - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - sklerosi multipla - immunosuppressanti selettivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 u 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Europese Unie - Maltees - EMA (European Medicines Agency)

biomarin international limited - cerliponase alfa - ceroid-lipofuscinoses newronali - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - brineura huwa indikat għall-kura ta newronali ceroid lipofuscinosis tat-tip 2 (cln2) il-marda, magħrufa wkoll bħala tripeptidyl peptidase 1 (tpp1), defiċjenza.

Europese Unie - Maltees - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosoppressanti - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 u 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Europese Unie - Maltees - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - neoplasmi prostatiċi - terapija endokrinali - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Europese Unie - Maltees - EMA (European Medicines Agency)

eli lilly nederland b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - homeostasi tal-kalċju - trattament ta 'l-osteoporożi f'nisa wara l-menopawża u fl-irġiel b'riskju akbar ta' ksur. f'nisa wara l-menopawża, intwera tnaqqis sinifikanti fl-inċidenza ta 'ksur vertebrali u mhux vertebrali iżda mhux fratturi tal-ġenbejn. trattament ta 'osteoporożi assoċjat ma sostnut sistemika terapija bi glukokortikojdi f'nisa u l-irġiel f'riskju akbar ta' ksur.

Europese Unie - Maltees - EMA (European Medicines Agency)

sandoz gmbh - ibandronic acid - breast neoplasms; neoplasm metastasis; fractures, bone - mediċini għall-kura ta'mard fl-għadam, bisphosphonates - sandoz aċidu ibandronic huwa indikat għall-prevenzjoni ta ' l-iskeletru avvenimenti (fratturi patoloġiċi, għadam komplikazzjonijiet li jeħtieġu radjoterapija jew kirurġija) fil-pazjenti bl-metastaΩi tal-kanċer u l-għadma tas-sider.